IL23A, Risankizumab Biosimilar

Größe

£512.00

SKU:: 592158
Reinheit:: Purified by Protein A/G affinity chromatography. ≥95%. Endotoxin: ≤1EU/mg (LAL)
Lagerbedingungen:: -20°C
Hersteller:: United States Biological
Host:: Human
Immunogen:: Recombinant protein corresponding to human IL-23alpha, expressed in CHO cells.
Format:: Supplied as a liquid in PBS. No preservative added.
Weitere Details:: Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) that is selective for interleukin 23 (IL-23). On April 23, 2019 it was approved by the FDA (as SKYRIZI) for the treatment of moderate-to-severe plaque psoriasis in adults who are clinically considered eligible for systemic therapy or phototherapy for psoriasis.Label This drug has been commercialized through collaboration between the German pharmaceutical company, Boehringer Ingelheim, and Abbvie. Applications: Suitable for use in Functional Assays. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.